logo-loader
viewNetscientific PLC

NetScientific portfolio company Vortex Biosciences appoints new chief executive officer

NetScientific said Bob Englert, who is currently chief technology officer, takes up the position with immediate effect, replacing Gene Walther

agreement
Vortex has also appointed Steve Crouse, who has been chief commercial officer since March 2016, to the position of chief operating officer

NetScientific PLC (LON:NSCI) has announced that its portfolio company Vortex Biosciences has appointed Bob Englert as new chief executive officer.

The healthcare IP commercialisation group said Bob Englert, who is currently chief technology officer, takes up the position with immediate effect, replacing Gene Walther, who has resigned to pursue other interests.

READ: NetScientific portfolio company ProAxsis receives grant by Invest North Ireland

The company said Bob Englert, who has been chief technology officer of Vortex since 2016, has over 25 years of global experience in medical devices and life sciences, with a particular focus on IVD, Point of Care, digital health solutions.

Vortex has also appointed Steve Crouse, who has been chief commercial officer since March 2016, to the position of chief operating officer. He will work closely with Bob Englert and the board to drive R&D and commercialisation strategies.

François R. Martelet, CEO of NetScientific and chairman of Vortex Biosciences, said: “Vortex is approaching a critical commercialisation phase with its unique CTC isolation technology, and Bob is in a unique position to drive this forward.”

He added: “With expertise gained from his role as chief technology officer and underpinned by years of industry experience, particularly in the diagnostics field, we believe he is the right person to take Vortex through the next phase of its growth.”

Quick facts: Netscientific PLC

Price: 6 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read